CSIMarket
 


Enanta Pharmaceuticals Inc  (ENTA)
Other Ticker:  
 
 

ENTA's Operating Income Growth by Quarter and Year

Enanta Pharmaceuticals Inc's Operating Income results by quarter and year




ENTA Operating Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter September -31.03 -27.05 -33.73 -19.78
III Quarter June -36.71 -32.54 -33.85 -22.85
II Quarter March -39.45 -33.85 -29.70 -11.88
I Quarter December -30.01 -30.41 -12.30 12.87
FY   -137.20 -123.85 -109.58 -41.64



ENTA Operating Income fourth quarter 2023 Y/Y Growth Comment
Enanta Pharmaceuticals Inc in the fourth quarter 2023 recorded Operating Loss of $ -31.03 millions.

According to the results reported in the fourth quarter 2023, Enanta Pharmaceuticals Inc achieved the best Operating Income growth in Major Pharmaceutical Preparations industry. While Enanta Pharmaceuticals Inc' s Operating Income no change of % ranks overall at the positon no. in the fourth quarter 2023.

Explain Operating Income growth


ENTA Operating Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter September - - - -
III Quarter June - - - -
II Quarter March - - - -
I Quarter December - - - -53.8 %
FY   - - - -

Financial Statements
Enanta Pharmaceuticals Inc's fourth quarter 2023 Operating Income $ -31.03 millions ENTA's Income Statement
Enanta Pharmaceuticals Inc's fourth quarter 2022 Operating Income $ -27.05 millions Quarterly ENTA's Income Statement
New: More ENTA's historic Operating Income Growth >>


ENTA Operating Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter September - - - -
III Quarter June - - - -
II Quarter March - - - -
I Quarter December - - - 100.16 %
FY (Year on Year)   - - - -




Operating Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Enanta Pharmaceuticals Inc's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ENTA's IV. Quarter Q/Q Operating Income Comment
Despite the fact, that Enanta Pharmaceuticals Inc in the IV. Quarter 2023 revealed Operating Loss of $ -31.03 millions, it should be said, that current results are improvement relative to the -36.71 millions in the third quarter.

Within Major Pharmaceutical Preparations industry Enanta Pharmaceuticals Inc achieved highest sequential Operating Income growth. While Enanta Pharmaceuticals Inc's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ENTA's IV. Quarter Q/Q Operating Income Comment
Even if Enanta Pharmaceuticals Inc in the IV. Quarter 2023 revealed Operating Loss of $ -31.03 millions, some analyst said, that current results are slight up side relative to the -36.71 millions in the third quarter.

Within Major Pharmaceutical Preparations industry Enanta Pharmaceuticals Inc achieved highest sequential Operating Income growth. While Enanta Pharmaceuticals Inc's Operating Income growth quarter on quarter, overall rank is .


Enanta Pharmaceuticals Inc's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Operating Income 12 Months Ending $ -137.21 $ -133.23 $ -129.05 $ -123.45 $ -123.84
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Enanta Pharmaceuticals Inc' has realized cumulative trailing twelve months Operating Loss of $ -137 millions in the Sep 30 2023 period.
The results are getting worse as the cumulative Operating Loss is getting bigger from $ -133.23 millions in the twelve months ending a quarter before and $ -130.523 millions for the twelve months ending in the quarter Sep 30 2022 Tyler Martin told.

Enanta Pharmaceuticals Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Enanta Pharmaceuticals Inc' has realized cumulative trailing twelve months Operating Loss of $ -137 millions in the Sep 30 2023 period.
The situation is detiriorating as the cumulative Operating Loss is getting bigger from $ -133.23 millions in TTM ending quarter Jun 30 2023 and $ -130.523 millions for the twelve months ending in the quarter Sep 30 2022 Tyler Martin told.

Enanta Pharmaceuticals Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Major Pharmaceutical Preparations Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
ENTA's Operating Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for ENTA's Competitors
Operating Income Growth for Enanta Pharmaceuticals Inc's Suppliers
Operating Income Growth for ENTA's Customers

You may also want to know
ENTA's Annual Growth Rates ENTA's Profitability Ratios ENTA's Asset Turnover Ratio ENTA's Dividend Growth
ENTA's Roe ENTA's Valuation Ratios ENTA's Financial Strength Ratios ENTA's Dividend Payout Ratio
ENTA's Roa ENTA's Inventory Turnover Ratio ENTA's Growth Rates ENTA's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2023
Becton Dickinson And Company25.54%$ 25.540 millions
Conmed Corporation24.96%$ 24.959 millions
Sotera Health Company20.42%$ 20.418 millions
Biomx Inc 19.03%$ 19.026 millions
Shockwave Medical Inc 18.66%$ 18.660 millions
Intuitive Surgical Inc 16.77%$ 16.771 millions
Nature s Sunshine Products inc 16.36%$ 16.361 millions
Align Technology inc 15.79%$ 15.795 millions
Stryker Corp15.22%$ 15.223 millions
Encompass Health Corporation14.02%$ 14.021 millions
Idexx Laboratories Inc12.44%$ 12.439 millions
Envista Holdings Corporation11.81%$ 11.812 millions
Surgery Partners Inc 11.47%$ 11.471 millions
Medpace Holdings Inc 9.10%$ 9.098 millions
Zoetis Inc 9.07%$ 9.066 millions
Zimmer Biomet Holdings Inc 8.68%$ 8.683 millions
Amedisys Inc 8.43%$ 8.425 millions
Hca Healthcare Inc 7.79%$ 7.787 millions
Chemed Corporation7.41%$ 7.412 millions
Ensign Group Inc7.41%$ 7.410 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com